A series of novel N-anilino-5-methyl-2-(3-(5-(alkylaminomethyl)furan-2-yl-methylthio)propyl)-[1,2,4]triazolo-[1,5-a]pyrimidine-7-amine derivatives were synthesized and evaluated for their in vitro cytotoxicity against two cancer cell lines, Bel-7402 and HT-1080. Compounds 9, 14, 19 and 23 possessed marked cytotoxicity, especially 23 (with IC50 values of 15.0 μM and 7.8 μM against Bel-7402 and HT-1080 cell lines, respectively), which had emerged as lead compound. The activity was found to depend strongly on substitution pattern of the side chains at C-2 position, and 4-triflouromethylanilino substituent at C-7 position was an option for anticancer potency.
                                    一系列新型N-
苯胺基-5-甲基-2-(3-(5-(烷
氨基甲基)
呋喃-2-基-甲
硫基)丙基)-[1,2,4]三唑并-[1,5-a]
嘧啶-7-胺衍
生物被合成并对其体外抗癌活性进行了测试,对象为Bel-7402和HT-1080两种癌细胞株。化合物9、14、19和23具有显著的细胞毒性,尤其是23号化合物(对Bel-7402和HT-1080细胞株的IC50值分别为15.0微摩尔和7.8微摩尔),已被选为先导化合物。活性主要取决于C-2位置上的侧链取代模式,而在C-7位置上使用4-三
氟甲基
苯胺基取代可以增强抗癌效力。